A landmark study drawing on data from UK Biobank has generated a first-of-its-kind dataset of the interactions between genes and proteins that could unlock myriad avenues
UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the
Researchers in Finland have combined virtual drug screening with machine learning (ML) – carried out on supercomputers – to dramatically shorten the time taken to identify
German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus
AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that